Cheng Xiang Foo

Mr. Cheng Xiang Foo

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2023 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
CFCheng Xiang Foo
Cheng Xiang Foo
SBStacey Bartlett
Stacey Bartlett
KCKeng Yih Chew
Keng Yih Chew
MNMinh Dao Ngo
Minh Dao Ngo
HBHelle Bielefeldt-Ohmann
Helle Bielefeldt-Ohmann
KRKatharina Ronacher
Katharina Ronacher
Rationale: Severe viral respiratory infections are often characterised by extensive myeloid cell infiltration and activation and persistent lung tissue injury. However, the immunological mechanisms driving excessive inflammation in the lung remain poorly understood.Objectives: To identify the mechanisms that drive immune cell recruitment in the lung during viral respiratory infections and identify novel drug targets to reduce inflammation and disease severity.Methods: Preclinical murine models of influenza A virus and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.Results: Oxidised cholesterols and the oxysterol-sensing receptor GPR183 were identified as drivers of monocyte/macrophage infiltration to the lung during influenza A virus (IAV) and SARS-CoV-2 infection. Both IAV and SARS-CoV-2 infection upregulated the enzymes cholesterol 25-hydroxylase (CH25H) and cytochrome P450 family 7 subfamily member B1 (CYP7B1) in the lung, resulting in local production of the oxidised cholesterols 25-hydroxycholesterol (25-OHC) and 7α,25-dihydroxycholesterol (7α,25-OHC). Loss-of-function mutation of Gpr183 or treatment with a GPR183 antagonist reduced macrophage infiltration and inflammatory cytokine production in the lungs of IAV- or SARS-CoV-2-infected mice. The GPR183 antagonist significantly attenuated the severity of SARS-CoV-2 infection and viral loads. Analysis of single-cell RNA-sequencing data on bronchoalveolar lavage samples from healthy controls and COVID-19 patients with moderate and severe disease revealed thatCH25H,CYP7B1andGPR183are significantly upregulated in macrophages during COVID-19.Conclusion: This study demonstrates that oxysterols drive inflammation in the lungviaGPR183 and provides the first preclinical evidence for the therapeutic benefit of targeting GPR183 during severe viral respiratory infections.

7 January 2022 in Cells
Verified
Journal Article
Open access
PDF file
CFCheng Xiang Foo
Cheng Xiang Foo
SBStacey Bartlett
Stacey Bartlett
KRKatharina Ronacher
Katharina Ronacher
Oxidized cholesterols, the so-called oxysterols, are widely known to regulate cholesterol homeostasis. However, more recently oxysterols have emerged as important lipid mediators in the response to both bacterial and viral infections. This review summarizes our current knowledge of selected oxysterols and their receptors in the control of intracellular bacterial growth as well as viral entry into the host cell and viral replication. Lastly, we briefly discuss the potential of oxysterols and their receptors as drug targets for infectious and inflammatory diseases.

10 December 2023 in The FASEB Journal
Verified
Journal Article
Closed access
JRJessica L. Ray
Jessica L. Ray
BPBritten Postma
Britten Postma
RKRebekah L. Kendall
Rebekah L. Kendall
MNMinh Dao Ngo
Minh Dao Ngo
CFCheng Xiang Foo
Cheng Xiang Foo
AHAndrij Holian
Andrij Holian

15 July 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
SBStacey Bartlett
Stacey Bartlett
AGAdrian Tandhyka Gemiarto
Adrian Tandhyka Gemiarto
MNMinh Dao Ngo
Minh Dao Ngo
HSHaressh Sajiir
Haressh Sajiir
SHSemira Hailu
Semira Hailu
KRKatharina Ronacher
Katharina Ronacher
Oxidized cholesterols have emerged as important signaling molecules of immune function, but little is known about the role of these oxysterols during mycobacterial infections. We found that expression of the oxysterol-receptor GPR183 was reduced in blood from patients with tuberculosis (TB) and type 2 diabetes (T2D) compared to TB patients without T2D and was associated with TB disease severity on chest x-ray. GPR183 activation by 7α,25-hydroxycholesterol (7α,25-OHC) reduced growth of Mycobacterium tuberculosis (Mtb) and Mycobacterium bovis BCG in primary human monocytes, an effect abrogated by the GPR183 antagonist GSK682753. Growth inhibition was associated with reduced IFN-β and IL-10 expression and enhanced autophagy. Mice lacking GPR183 had significantly increased lung Mtb burden and dysregulated IFNs during early infection. Together, our data demonstrate that GPR183 is an important regulator of intracellular mycobacterial growth and interferons during mycobacterial infection. Graphical

28 June 2024
Verified
Thesis
Closed access
CFCheng Xiang Foo
Cheng Xiang Foo
The University of Queensland's institutional repository, UQ eSpace, aims to create global visibility and accessibility of UQ’s scholarly research.

24 February 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
MWMelanie Wu
Melanie Wu
JSJulian D. J. Sng
Julian D. J. Sng
ENEllesandra C. Noye
Ellesandra C. Noye
GMGeorgina McCallum
Georgina McCallum
Helle Bielefeldt-OhmannHelle Bielefeldt-Ohmann
Helle Bielefeldt-Ohmann
Kirsty ShortKirsty Short
Kirsty Short
Dysregulation of the renin-angiotensin system (RAS) contributes to severe influenza and COVID-19, potentially via impaired ACE2/Ang-(1-7)/Mas receptor (MasR) signalling. AVE0991, an orally bioavailable MasR agonist, protects against non-infectious lung inflammation, but its effects in viral respiratory disease are unknown. We evaluated AVE0991 in human lung epithelial cells and murine models of influenza A virus (IAV) and SARS-CoV-2 infection. In vitro , AVE0991 suppressed cytokines IL-6 and TNF-α to both IAV and SARS-CoV-2 and reduced IAV titres. Unexpectedly, in vivo treatment worsened disease. These findings highlight discordant in vitro and in vivo effects and underscore the need for careful evaluation of RAS-targeted therapies in acute viral infection.